Stock search

Ticker or company name

Biogen

BIIB · NASDAQ · Biotechnology

$251,65Down −1,75 (−0,69%)today

Quotes delayed up to 15 min. Updated 16 Nov, 16:00 New York time

Market cap
$37,5 bn
Div. yield
—
Year to date
+44,0%
52 weeks: $160,36$261,00

Ratio score

31/100
Ratio would not consider buying

based on 8 metrics as of 16.11.2026 ·

Verdict by our methodology based on current metrics. Not an investment recommendation.

Key metrics

1 ✓ · 3 — · 4 ✕ · 2 n/a · hover over a row or tap it to see the trend

All metrics

MetricValue5-year medianIndustry median
P/E TTM107,818,542,1
Forward P/E16,5—18,7
PEG22,4—4,1
P/S3,63,26,6
EV/EBITDA36,213,028,2
P/FCF22,1—26,0
P/B2,02,19,8

Industry median — across 6 profitable companies in “Biotechnology” in Ratio. Revenue and EPS forecasts for future years and the number of employees are in the paid data plan.

Price chart

Compare with

Choose a stock

Closing prices adjusted for splits and dividends. The S&P 500 index and the intraday chart come later.

Analysts

Ratings, 44 analysts

Buy
32
Hold
11
Sell
1

Beat the EPS forecast in 4 of the last 4 quarters

QuarterEstimateActualSurprise
Q3 20262,032,62Up +28,9%
Q2 20263,013,60Up +19,8%
Q1 20262,833,57Up +26,3%
Q4 20251,651,99Up +20,9%

Price targets and yearly revenue and EPS forecasts are in the paid data plan. These are analysts' opinions, not our verdict.

Financials in charts

MetricQ3'26Q2'26Q1'26Q4'25Q3'25Q2'25Q1'25Q4'24Q3'24Q2'24Q1'24Q4'23
Revenue2,80 bn2,74 bn2,48 bn2,28 bn2,53 bn2,65 bn2,43 bn2,45 bn2,47 bn2,46 bn2,29 bn2,39 bn
EPS−0,140,662,15−0,353,174,331,641,832,664,002,701,71
Margin−0,7%3,6%12,9%−2,1%18,4%24,0%9,9%10,9%15,8%23,7%17,2%10,5%
FCF600 m408 m594 m468 m1,23 bn134 m222 m722 m901 m592 m507 m−52,7 m

From SEC reports. TTM is the sum of 4 quarters; a year is TTM at the end of the calendar year. Forecast bars are in the paid data plan.

Owners

Ownership structure and major holders (13F filings) are in the paid data plan. They are not part of the score or the traffic light.

Insider trades over 12 months

Over 12 months: purchases $585 (1 person), sales $905 414.

NameAmountSharesPrice
minor lloyd4 Aug 2026 · sale$119 169593$200,96
minor lloyd3 Aug 2026 · sale$120 581593$203,34
murphy nicole12 Feb 2026 · open-market purchase$5853$195,04
singhal priya9 Feb 2026 · sale$531 5482 660$199,83
singhal priya2 Feb 2026 · sale$134 116748$179,30

SEC Form 4. Titles and trading plans are not in the data. They are not part of the score or the traffic light.

About the company

Industry
Biotechnology
Exchange
NASDAQ
Country
US
IPO date
17 Sep 1991

Company description, revenue by segment and region, and the CEO will come later.

Next report
date not announced

An AI summary of the earnings call will come later.

Peers

CompanyPrice
INCYIncyte$120,2744would watch61,1+24,9%6,7%
MRNAModerna$215,2722would not consider—+13,1%−110,5%
REGNRegeneron Pharmaceuticals$952,4067would watch20,5+18,6%28,5%
VRTXVertex Pharmaceuticals$537,7972would consider33,7+10,5%30,7%
GILDGilead Sciences$167,5825would not consider—+6,5%−12,5%
Compare with peers

Ratio — a score by our methodology, not an investment recommendation.